Repligen (NASDAQ:RGEN) Rating Increased to Buy at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a research report sent to investors on Wednesday, MarketBeat.com reports. They currently have $155.00 price target on the biotechnology company’s stock, down from their previous price target of $180.00.

RGEN has been the topic of several other reports. Guggenheim started coverage on shares of Repligen in a report on Tuesday, June 18th. They issued a neutral rating on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of Moderate Buy and an average target price of $193.00.

Repligen Stock Down 0.4 %

NASDAQ:RGEN opened at $126.06 on Wednesday. The company has a market cap of $7.04 billion, a PE ratio of 504.26, a P/E/G ratio of 4.24 and a beta of 1.04. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The company’s 50 day moving average is $151.71 and its two-hundred day moving average is $173.86.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.64 EPS. Analysts anticipate that Repligen will post 1.46 EPS for the current year.

Insider Activity at Repligen

In related news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Martin D. Madaus acquired 1,615 shares of Repligen stock in a transaction on Friday, June 14th. The stock was bought at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the transaction, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the stock. YHB Investment Advisors Inc. acquired a new position in Repligen during the first quarter worth $26,000. Lazard Asset Management LLC raised its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in Repligen by 152.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 146 shares during the period. Principal Securities Inc. acquired a new stake in shares of Repligen in the fourth quarter valued at about $48,000. Finally, CWM LLC raised its position in shares of Repligen by 19.9% in the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.